leisure time -WSS

leisure time

author：focus 2025-09-03 06:18:27 - browse：323

LONDON — AstraZeneca said Tuesday it would acquire Fusion Pharmaceuticals in a deal worth more than $2 billion, picking up a company focused on the booming area of targeted radiation therapies for cancer.

AstraZeneca will pay $2 billion in cash upfront for Fusion, a price that at $21 a share is nearly double Fusion’s closing share price on Monday. If certain regulatory milestones are met, AstraZeneca will pay another $3 a share, or roughly $400 million.

Fusion specializes in developing radiopharmaceuticals, also known as radioconjugates or radioligands, which deliver radiation directly to tumors, guided by particular markers on cancer cells. The aim is not only to minimize the risk of damaging surrounding, healthy tissue, but also to reach tumors that traditional radiation can’t.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

WSS

Biotech reporter’s notebook: A sunnier mood at JPM 2024

Readout Newsletter: Bristol, Sangamo, Gilead, and more

Medicare coverage of Wegovy, once blocked, now looks possible

WuXi out of biotech trade group, U.S. and China relations to blame

Readout Newsletter: Bristol, Sangamo, Gilead, and more

The nurse manager staffing crisis is hurting patients

explore

leisure time

Wikipedia

DIEP, the 'gold standard' of breast reconstruction, is under threat

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

How one medical school became remarkably diverse

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

As JPM 2024 winds down, some health tech firms project optimism

At least 13 dead in Texas as scorching temps continue

Pushing for an NIH office for post

Peter Hotez and the public health issue of online harassment

DeSantis can now import cheaper drugs. But will Biden get credit?

focus

How to save health care price transparency rules

Boston's new lab space is opening empty

Doulas covered by Medicaid under New York's new plan

The SUPPORT Act is critical to fighting the opioid crisis

Idaho abortion case may prompt more restrictions in other states

Risky weight loss products often used by teens globally, per study

knowledge

hotspot

leisure time

hotspot